GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
38.58
+0.03 (0.08%)
At close: Jun 27, 2025, 4:00 PM
38.75
+0.17 (0.44%)
After-hours: Jun 27, 2025, 7:56 PM EDT
GSK Revenue
GSK had revenue of 7.52B GBP in the quarter ending March 31, 2025, with 2.08% growth. This brings the company's revenue in the last twelve months to 31.53B, up 2.57% year-over-year. In the year 2024, GSK had annual revenue of 31.38B with 3.46% growth.
Revenue (ttm)
31.53B GBP
Revenue Growth
+2.57%
P/S Ratio
1.94
Revenue / Employee
459,412 GBP
Employees
68,629
Market Cap
79.09B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | 24.35B | -9.40B | -27.85% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
GSK News
- 1 day ago - US Senator investigates GSK for pulling children's asthma inhaler - Reuters
- 3 days ago - Bharat, GSK to halve price of malaria vaccine by 2028 - Reuters
- 4 days ago - FDA approves Benlysta (belimumab) Autoinjector for children with active lupus nephritis - Business Wire
- 12 days ago - GSK announces the Linked by Lupus: Optimal Care Initiative to help support individuals with lupus in the US - Business Wire
- 15 days ago - GSK says EU heath regulator reviewing expansion of RSV vaccine - Reuters
- 19 days ago - Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
- 26 days ago - Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - PRNewsWire
- 4 weeks ago - Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday? - Benzinga